|
他汀類藥物在神經(jīng)科和心內(nèi)科可謂是遍地開(kāi)花。調(diào)控血脂、降低心腦血管疾病的發(fā)病率是它們的本職。 為什么需要夜間服用？  為什么不需要夜間服用？ 要點(diǎn)小結(jié)  參考文獻(xiàn)： [1]. Desai, C.S., S.S. Martin and R.S. Blumenthal, Non-cardiovascular effects associated with statins. BMJ, 2014. 349: p. g3743. [2]. 中華醫(yī)學(xué)會(huì)神經(jīng)病學(xué)分會(huì)與中華醫(yī)學(xué)會(huì)神經(jīng)病學(xué)分會(huì)腦血管病學(xué)組, 中國(guó)缺血性腦卒中和短暫性腦缺血發(fā)作二級(jí)預(yù)防指南 2014. 中華神經(jīng)科雜志, 2015. 48(4): 第 258-273 頁(yè). [3]. Lund, T.M., et al., Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease. Am J Cardiol, 2002. 90(7): p. 784-6. [4]. Wallace, A., D. Chinn and G. Rubin, Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ, 2003. 327(7418): p. 788. [5]. Illingworth, D.R., Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther, 1986. 40(3): p. 338-43. [6]. Hunninghake, D.B., et al., Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. Atherosclerosis, 1990. 85(2-3): p. 219-27. [7]. Muck, W., et al., Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening. Int J Clin Pharmacol Ther, 2000. 38(6): p. 298-303. [8]. Scharnagl, H., et al., Efficacy and safety of fluvastatin-extended release in hypercholesterolemic patients: morning administration is equivalent to evening administration. Cardiology, 2006. 106(4): p. 241-8. [9]. Fauler, G., et al., Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics. Int J Clin Pharmacol Ther, 2007. 45(6): p. 328-34. [10]. Yi, Y.J., et al., Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia. Clin Ther, 2014. 36(8): p. 1182-90. [11]. Cilla, D.J., et al., Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol, 1996. 36(7): p. 604-9. [12]. Martin, P.D., P.D. Mitchell and D.W. Schneck, Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol, 2002. 54(5): p. 472-7. [13]. 查錫良. 生物化學(xué)（第七版）. 北京：人民衛(wèi)生出版社，2013.[14]. UpToDate 臨床決策數(shù)據(jù)庫(kù) www.uptodate.com |
|
|
來(lái)自： 妃子笑1025 > 《心血管護(hù)理》
